Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, kappa antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Reinheit:
96.0%
CAS Nummer:
[1660159-36-3]
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten